The pharmaceutical company Double Bond Pharmaceutical is starting a collaboration with Karolinska Institutet for the analysis of real-world data on the cancer treatment Temodex. A researcher from KI will contribute advanced statistical and clinical methodology.The analysis includes data from over 480 patients and aims to strengthen the clinical evidence. Results are expected to be presented at a medical congress in 2026. No financial details are provided."Collaborating with Karolinska Institutet, one of the world's leading medical universities, is a significant step for us," says Igor Lokot, CEO of Double Bond Pharmaceutical. He continues. "By integrating a highly qualified researcher into our team, we can apply more sophisticated analytical models to our RWE dataset. This not only prepares us for our upcoming presentation at the EANS 2026 congress in Hamburg, but also strengthens the clinical evidence required to take Temodex to the global market."